Cohort of patients with plasma cell disorders at Peking University First Hospital

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a prospective cohort of hospitalized patients diagnosed with plasma cell disorders (PCDs) at Peking University First Hospital. It will collect clinical characteristics, treatment options, and responses, along with biological samples such as peripheral blood, bone marrow aspirate, and urine for future research. The study will focus on analyzing the correlation between minimal residual disease (MRD) status and prognosis, as well as the role of the tumor microenvironment (TME) in the pathogenesis and progression of PCDs. Follow-up assessments will occur at various intervals post-treatment to monitor patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH)
2. Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS).
3. Patients are included into this cohort after signing the ICFs.

Exclusion Criteria:

Significant comorbidity may be life-threatening.

Where it's running

• Peking University First Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Bo Tang, PhD
• Email: tangbo8809@163.com
• Phone: 008613521776195

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for adults with plasma cell disorders

  This study is creating a registry for adults with plasma cell disorders like multiple myeloma to track their health and care experiences over time while also collecting blood samples for future research.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT03717844

• Collection and analysis of biological samples from patients with multiple myeloma and related conditions

  This study is collecting and storing blood samples from patients with multiple myeloma and similar conditions to help researchers learn more about these diseases and improve treatments.

  Recruiting at 41 sites European Myeloma Network B.V. · Melbourne and 40 other locations · NCT06237803

• Registry for older adults with blood cancers

  This study is creating a registry for older adults with blood cancers to see how their health changes over time and to support future research.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT05556928

• Prolonged overnight fasting combined with a Mediterranean-style diet for people with multiple myeloma or precursor conditions

  This program will test whether longer overnight fasting paired with a Mediterranean-style eating plan is doable for adults with MGUS, smoldering myeloma, or newly diagnosed multiple myeloma who are starting treatment.

  Recruiting University of Miami · Miami, Florida · NCT07446777

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.